CAMBRIDGE, Mass., Oct. 30, 2023 /PRNewswire/ — Ahead of the 38th annual meeting of the Society for Immunotherapy of Cancer (SITC), Ultivue today announced the launch of OmniVUE™, a unique portfolio of fully customizable biomarker panels for multiplex immunofluorescence analysis of the tumor immune microenvironment. Researchers can now select any combination of up to 8 biomarkers from Ultivue’s validated biomarker core library and design OmniVUE panels tailored to their specific biological questions. Pre-optimized ready-to-use kits with OmniVUE panels will be delivered within four weeks of request, with no additional development costs.  

Read the full article on PR Newswire.